ONCAlert | Upfront Therapy for mRCC
Videos  >  

Benefit With Cemiplimab in Patients With mCSCC

Danny Rischin, MD, MBBS, FRACP
Published Online:5:56 PM, Tue December 18, 2018

Danny Rischin, MD, MBBS, FRACP, director, division of cancer medicine, and head, department of medical oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, shares his insights on cemiplimab (Libtayo) as a treatment for patients with metastatic cutaneous squamous cell carcinoma (mCSCC).

These patients most often have advanced disease with limited treatment options. They are usually elderly patients with a prognosis of only 6- to 12-month survival, Rischin says. Cemiplimab is a remarkable agent in this setting, and some patients have even gone on to their normal lives with nearly 2-year survival.
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.